CADTH | Search

Current Filters

Showing 61 - 70 results of 3551

Evusheld for the Treatment of Mild to Moderate COVID-19 (Last Updated: Oct 26, 2022)

Tixagevimab and cilgavimab (Evusheld) is a combination of long-acting monoclonal antibodies for intramuscular administration for the treatment of mild to moderate COVID-19. CADTH conducted a review of...
Project Line:
Health Technology Review
Project Status:
Completed

RWE Learning Project Non-Oncology: Ocaliva (Last Updated: Sep 8, 2022)

This is a new CADTH project. Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of...
Project Line:
Health Technology Review
Project Status:
In Progress

CADTH Pharmaceutical Reviews Update — Issue 31 () (Last Updated: Sep 1, 2022)

See Pharmaceutical Reviews Update ― Issue 31 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include: changes to filing new information during the...
Project Line:
Reimbursement Review

Almotriptan (Axert) (Last Updated: Dec 24, 2003)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Axert
Manufacturer:
Janssen-Ortho Inc.
Submission Type:
Initial
Indications:

Migraine

Norgelestromin/ethinyl estradiol (Evra) (Last Updated: Dec 19, 2003)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Evra
Manufacturer:
Janssen-Ortho Inc.
Submission Type:
Initial
Indications:

Contraceptive, patch

Gefitinib (Iressa) (Last Updated: Dec 22, 2003)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Iressa
Manufacturer:
AstraZeneca
Submission Type:
Initial
Indications:

Cancer, Lung , non-small cell

Download results as CSV